PDS Biotechnology Corp
PDSB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472091
No open-market purchases or sales by PDS Biotechnology Corp insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $6.78M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding PDS Biotechnology Corp changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 80 | +12 |
| Shares | 7.66M | 25.0K | 7.93M | +299.5K (+3.9%) |
| Value | $46.9M | $76.9K | $39.9M | −$6.91M (−14.8%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (31)
Institutions that held PDS Biotechnology Corp at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (19)
Institutions that held PDS Biotechnology Corp at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Millennium Management LLC | 596,272 | $3.67M |
| First Manhattan Co | 271,576 | $1.67M |
| Qube Research & Technologies Ltd | 201,083 | $1.24M |
| Cubist Systematic Strategies, LLC | 163,507 | $1.01M |
| D. E. Shaw & Co., Inc. | 162,769 | $1.00M |
| HRT Financial LP | 88,385 | $543.0K |
| Trexquant Investment LP | 38,110 | $234.4K |
| Raymond James Financial Services Advisors, Inc. | 25,918 | $159.4K |
| Man Group plc | – | $109.7K |
| LMR Partners LLP | 17,520 | $107.7K |
| Total Clarity Wealth Management, Inc. | 14,362 | $88.3K |
| Boothbay Fund Management, LLC | 11,507 | $70.8K |
| Quantbot Technologies LP | 8,722 | $53.6K |
| Point72 Asset Management, L.P. | 7,811 | $48.0K |
| Point72 Middle East FZE | 3,766 | $23.2K |
| Belpointe Asset Management LLC | 755 | $4.64K |
| TCI Wealth Advisors, Inc. | 200 | $1.23K |
| Federated Hermes, Inc. | 123 | $756 |
| EP Wealth Advisors, LLC | 38,337 | – |
Not filed for Q2 2023 yet (1)
Institutions that held PDS Biotechnology Corp at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Andesa Financial Management Inc. | 25,000 | $76.9K |